Teladoc Health (NYSE:TDOC) Price Target Lowered to $25.00 at Canaccord Genuity Group

Teladoc Health (NYSE:TDOC) had its price objective trimmed by Canaccord Genuity Group from $28.00 to $25.00 in a research report report published on Friday morning, Benzinga reports. The firm currently has a buy rating on the health services provider’s stock.

TDOC has been the subject of several other research reports. Truist Financial lowered their price target on shares of Teladoc Health from $23.00 to $17.00 and set a hold rating for the company in a research report on Wednesday, March 6th. SVB Leerink started coverage on shares of Teladoc Health in a report on Monday, February 26th. They set a market perform rating and a $17.00 price target for the company. Piper Sandler dropped their target price on shares of Teladoc Health from $30.00 to $25.00 and set an overweight rating on the stock in a research report on Wednesday, February 21st. DA Davidson dropped their target price on shares of Teladoc Health from $22.00 to $18.00 and set a neutral rating on the stock in a research report on Wednesday, February 21st. Finally, Cantor Fitzgerald began coverage on shares of Teladoc Health in a report on Thursday, February 29th. They issued an overweight rating and a $22.00 price target on the stock. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of Hold and a consensus target price of $19.67.

Teladoc Health Price Performance

Shares of TDOC stock opened at $13.01 on Friday. The firm has a fifty day simple moving average of $15.01 and a 200-day simple moving average of $17.77. The company has a debt-to-equity ratio of 0.66, a quick ratio of 3.47 and a current ratio of 3.54. Teladoc Health has a twelve month low of $12.65 and a twelve month high of $30.41.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Thursday, April 25th. The health services provider reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.02). The company had revenue of $646.13 million during the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.11%. The company’s revenue was up 2.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.37) earnings per share. Equities analysts expect that Teladoc Health will post -1.07 EPS for the current year.

Insiders Place Their Bets

In other news, insider Laizer Kornwasser sold 7,882 shares of the company’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total transaction of $151,176.76. Following the transaction, the insider now owns 57,223 shares of the company’s stock, valued at approximately $1,097,537.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CAO Richard J. Napolitano sold 3,765 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $54,667.80. Following the completion of the sale, the chief accounting officer now directly owns 18,077 shares in the company, valued at approximately $262,478.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Laizer Kornwasser sold 7,882 shares of the stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $19.18, for a total value of $151,176.76. Following the completion of the sale, the insider now owns 57,223 shares of the company’s stock, valued at approximately $1,097,537.14. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 135,441 shares of company stock valued at $2,038,251. Insiders own 1.63% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Parallel Advisors LLC increased its position in Teladoc Health by 14.6% during the fourth quarter. Parallel Advisors LLC now owns 4,038 shares of the health services provider’s stock valued at $87,000 after acquiring an additional 515 shares during the last quarter. M&T Bank Corp increased its position in Teladoc Health by 5.5% during the fourth quarter. M&T Bank Corp now owns 11,152 shares of the health services provider’s stock valued at $241,000 after acquiring an additional 584 shares during the last quarter. Van ECK Associates Corp increased its position in Teladoc Health by 20.3% during the fourth quarter. Van ECK Associates Corp now owns 3,589 shares of the health services provider’s stock valued at $77,000 after acquiring an additional 606 shares during the last quarter. Arizona State Retirement System increased its position in Teladoc Health by 1.4% during the third quarter. Arizona State Retirement System now owns 46,602 shares of the health services provider’s stock valued at $866,000 after acquiring an additional 650 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in Teladoc Health by 4.3% during the third quarter. Victory Capital Management Inc. now owns 17,946 shares of the health services provider’s stock valued at $334,000 after acquiring an additional 748 shares during the last quarter. Institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.